Drug Detail

Information about THE-630

Generic Name
IND
THE-630
Brand Name (US)
Manufacturer
Theseus
Drug Type
Delivery
Oral
Approval Status
Indications
Overall Strategy
KIT Protein Based
Strategy
Block KIT
Drug Category
KIT Inhibitor

PDGFRA V561D (IC50 <5 nM)

THE-630 not designed to potently inhibit PDGFR D842V (GIST) and KIT D816V (mastocytosis) activating mutations
− IC50 >100 nM in BaF3 cellular assays.


Links

 

New IND announcement 11-1-2021 from Theseus
   

 

AACR 2021 Poster from Theseus
   

 

Theseus Corp Presentation 11/2021
   

Trials of this drug


Trial results


Search for this drug/combination in:

ClinicalTrials.gov

ASCO

Pubmed